Morison enters cardiovascular space by ‘Touching More Hearts’

Monday, 3 March 2025 03:55 - - {{hitsCtrl.values.hits}}

A panel discussion among esteemed medical specialists

Hemas Holdings Chairman Husein Esufally addressing the gathering at the launch of three advanced and promising therapies by Morison

Morison Managing Director Dinesh Athapaththu explaining Morison’s purpose and efforts behind the launch of advanced therapies

Morison, a pioneer in the Sri Lankan pharmaceutical manufacturing industry with over 60 years of expertise, last week announced their entry into the cardiovascular space with the launch of three advanced promising therapies: Cilnidipine Tablets IP 5mg and 10mg, Rivaroxaban Tablets 10mg and 20mg, and Bisoprolol Tablets BP 2.5mg and 5mg, all in 30s blister packs.

Cilnidipine and Rivaroxaban will be manufactured in Sri Lanka for the first time in Morison’s new state-of-the-art pharma manufacturing facility at Homagama.

The new cardiovascular portfolio includes CilniMor (Cilnidipine), a fourth generation calcium channel blocker for hypertension; BisoMor (Bisoprolol), a cardio-selective beta blocker; and RivoMor (Rivaroxaban), a direct factor Xa inhibitor anticoagulant. All medications are quality assured in compliance with pharmacopeial test parameters. Morison marked this historic milestone with a distinctive launch event attended by leading healthcare professionals and institutional officials at Cinnamon Grand, with the theme of ‘Touching More Hearts.’ The highlight of the evening was a panel discussion featuring eminent consultants representing cardiologists, endocrinologists, and physicians, who discussed the new therapies and their impact on Sri Lanka’s growing NCD challenges. Morison Ltd. Managing Director Dinesh Athapaththu said: “At Morison, we choose to take the high road. For us, it’s not just about churning out tablets. We are conscious of the fact that behind every tablet we produce is a person trusting us at their most vulnerable times. Therefore, for us it is not merely a business, but more of a responsibility we take to heart.”

Staying true to their purpose of ‘Making Premium Healthcare Affordable,’ Morison is committed to providing essential medications at significantly lower prices compared to current market rates. CilniMor will be available at Rs. 30 (5mg) and Rs. 45 (10mg) per tablet, RivoMor will be available at Rs. 60 (10mg) and Rs. 90 (20mg) per tablet, while BisoMor is priced at Rs. 15 (2.5mg) and Rs. 20 (5mg) per tablet. The pricing strategy has the potential to save patients up to Rs. 30,000+ annually, making these critical medications more accessible to Sri Lankan patients.

The launch of these therapies follows Morison’s successful introduction of EmpaMor (Empagliflozin 10mg and 25mg tablets), a diabetes medication that became the market leader within two years of launch.

Morison said it will continue to drive this transformative journey of building an exclusive home-grown pharmaceutical brand that is uniquely unparalleled, contributing to a more self-sufficient pharmaceutical market. With deep Sri Lankan roots and the backing of Hemas Holdings PLC, the company understands the nation’s healthcare needs and is committed to delivering the latest advanced therapies, combining quality and affordability, while committing to ensure integrity across their value chain.

Discover Kapruka, the leading online shopping platform in Sri Lanka, where you can conveniently send Gifts and Flowers to your loved ones for any event including Valentine ’s Day. Explore a wide range of popular Shopping Categories on Kapruka, including Toys, Groceries, Electronics, Birthday Cakes, Fruits, Chocolates, Flower Bouquets, Clothing, Watches, Lingerie, Gift Sets and Jewellery. Also if you’re interested in selling with Kapruka, Partner Central by Kapruka is the best solution to start with. Moreover, through Kapruka Global Shop, you can also enjoy the convenience of purchasing products from renowned platforms like Amazon and eBay and have them delivered to Sri Lanka.